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CHAPTER ONE 
INTRODUCTION 
General Information 	  
Although phenotypes can be changed through converting the information of 
DNA sequence, epigenetic changing also can make it. The initial definition of 
epigenetic is “the interactions between genes and their products leading to the 
realization of the phenotype” by Waddington. However, now it evolves to become 
more precisely that changes that can lead to a heritable and stable phenotype 
happens on a chromosome without changing its DNA sequence [1]. Epigenetic 
modifications such as DNA methylation, histone methylation, and histone acetylation 
play spectacular roles in physical process in life [2]. For example, histone acetylation 
and methylation as well as DNA methylation have influences on gene expression and 
repression. Among all the epigenetic modifications, DNA methylation is most likely 
best known and has been regarded as an important target for drug design, especially 
in cancer drug development. Aberrant DNA methylation has been proved that is 
associated with unplanned silencing based on two distinct forms: hypomethylation 
and hypermethylation. Global hypomethylation has something to do with the 
development and progression of cancer through different mechanisms. 
Hypermethylation is one of the major DNA methylation modifications that repress 
transcriptions of promoter regions in cancer cells’ suppressor genes. DNA 
methylation is a significant factor in regulating mammalian cells’ life cycle. Alterations 
in DNA methylation patterns can promote tumorigenesis and predispose genes to 
mutational events.  
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DNA Methyltransferases 	  
DNA methylation is catalyzed by DNA methyltransferases (DNMTs) using S-
Adenosyl-L- Methionine (SAM) as the methyl group donor. As recently, mammalian 
methyltransferases are divided into DNMT1, DNMT3 and TRDMT1 in which the 
TRDMT1 was named DNMT2 and does not methylate DNA rather a tRNAAsp [1]. 
They have C-terminal catalytic domain and N-terminal regulatory domain [3]. DNMT3 
is a de novo methyltransferase that is prevalent and expressed in embryonic stages 
and differentiated cells, which means it can effectively methylate unmethylated DNA, 
whereas DNMT1 can maintain DNA-methylation pattern during replication, which 
means it has a higher affinity for a hemimethylated DNA strands than the 
unmethylated ones just as the Fig.1 shows [4] [5]. However the sequence in catalytic 
sites of DNMT3A and DNMT3B shows a certain homology with DNMT1 [2].  
 
Figure.1 Scheme of DNA methylation. A. It is the action mode of DNMT3A/B. B. it is the action mode of DNMT1 
Produced from Moore, L.D., T. Le, and G. Fan, DNA methylation and its basic function. 
Neuropsychopharmacology, 2013. 38(1): p. 23-38. 
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Structure Analysis of DNA Methyltransferase 1 (DNMT1) 	  
Here we focus more on DNMT1, which has proved its potency for drug target 
in cancer therapies. Mammal DNMT1 is a protein with 1616 amino acids whose 
structure can be divided into a regulatory domain and a catalytic domain. Motif IV 
includes the cysteine residue that can act as nucleophile attacking cytosine in the 
substrate and forming a transient covalent bond. Sequences at the N-terminus end 
named DMAP has been approved that has interactions with DNA methyltransferase 
associated protein-1 [6]. It usually helps bind DNA at CG sites [7]. In DNMT1, CXXC 
domain involves eight conserved cysteine residues clustered in two CXXCXXC 
repeat. This domain is essential for the catalytic activity for the enzyme [8]. It has 
been observed that the isolated fragment of C-terminal catalytic domain does not 
have any activities without N-terminal regulatory domain [7] [9]. BAH domains are 
Bromo-adjacent homology domains. These domains involved in transcriptional 
regulation are present in several proteins. Although its function roles in DNMT1 
remain unclear, they have important role in protein-protein recognition and interaction 
in gene silencing [9].  
 
Figure.2 Primary structure of the DNMT1. Reproduced from http://www.frontiersin.org/files/Articles/132809/fgene-
06-00090-r2/image_m/fgene-06-00090-g002.jpg 
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DNA Methlation in Cancer 	  
In cancer cells, DNA methylation can lead to promoter hypermethylation at 
CpG islands and then silence tumor supprßessor genes [2]. Unlike mutagenic events, 
however, epigenetic mutations can be reversible. DNA demethylation of aberrantly 
silenced genes can recover gene expression [10]. In mammals, DNA methylation 
happens at the 5-position of cytosine in CpG dinucleotides and hypermethylation 
occurs in the CpG-rich sequences, which is called CpG island (regions with a high 
frequency of CpG sites). Gene expression can be manipulated through the action of 
repressor proteins that attach to silencing regions of the DNA. Because most CpG 
islands are involved in core promoters and transcription initiation, such as p16INK4a 
and human mutL homologure, the silence of genes can be triggered by 
hypermethylation because of poor recognition by transcription factors and 
recruitment of proteins, which are involved in the tumorigenic process [11]. Therefore, 
DNA methylation inhibitors are regarded as potential anticancer agents 
Structure Analysis of Models from PDB 	  
For now there is not any isolated human DNA methyltransferase crystal 
structures in free state available in Protein Data Bank (PDB). 3SWR and 3PTA are 
two complexes of human DNMT. 3SWR is structure of human DNMT1 in complex 
with Sinefungin and 3PTA is a crystal structure of human DNMT1 in complex with 
DNA. Both of them can be used to help design DNMT inhibitors. We found out that 
the sequence and tertiary structure of catalytic sites in mammal DNMT1 are 
conservative and the catalytic site is formed by two pockets, DNA binding pocket and 
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cofactor binding pocket are depicted in figure.3.  According to the research [12] there 
are several residues of the DNMT playing important roles in catalyzing methylation 
process, which could be taken advantage of designing new inhibitors. For example, 
Arg174, Arg318, Glu128 and His321 in the catalytic site can form hydrogen bonds 
with pentose rings, phosphate group, amino group and 3’-hydroxy group of cytidine 
respectively. Glu128 and Arg174 could be involved into the catalytic mechanism 
through stabilizing the intermediate [13-15].  
 
 
Figure.3 it shows the SAM (red) and Cytosine (green) in the catalytic site of DNMT1 (PDB: 
4DA4). The position SAM occupies is cofactor pocket and the position Cytosine occupies is DNA 
pocket. 
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                   PDB: 3SWR                                                                                       PDB: 3PTA 
Figure.4 3D structure of DNMT1 with different resourcesReproduced from 
http://www.rcsb.org/pdb/results/results.do?qrid=F05BBCF0&tabtoshow=Current 
 
The Working Mechanism of DNMT1 	  
The catalytic mechanism for the methylation of cytosine-5 has been discussed 
in detail several decades ago [16]. As depicted figure.5, a thiol group of the cysteine 
residue in the active site of DNMTs serves as a nucleophile that attacks the 6- 
position of cytosine to generate a covalent DNA-protein intermediate that possesses 
nucleophilic properties at the 5-position. This reactive intermediate accepts a methyl 
group from S-Adenosyl Methyionoine (SAM) to form a complex of 5-methyl covalent 
adduct and S-Adenosyl-L-Homocysteine (SAH). And the Glutamic acid in the active 
site is helpful for stabilizing the intermediate. Following the methyl transfer, a basic 
residue in the active site abstracts the proton at the 5-position and then the covalent 
bond formed between protein and thiol group was removed through ß- elimination to 
generate the methylated cytosine and the free enzyme [11]. 
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Figure.5 Scheme of catalytic process. 
Reproduced from http://chemistry.umeche.maine.edu/CHY431/Nucleic/Methylation.gif 
 
 
 
Inhibitors for DNMT1 	  
Two types of methyltransferase inhibitors have been developed in last several 
decades, categorized into nucleoside analogue inhibitors and non-nucleoside 
analogue inhibitors.  
Nucleoside inhibitors: In nucleoside inhibitor category, 5-azacytidine and 5-aza-2’-
deoxycytidine have been approved by FDA for treating myelodysplastic syndrome 
(MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia 
(CMML) [17].  
When nucleoside analogues are incorporated into DNA, for example 5-
azacytidine and 5-aza-2’-deoxycytidine, they can become substrates of the DNA 
replication. Azacytosine can be recognized as cytosine, which is a natural substrate 
for binding DNA methyltransferase and the enzyme will start the methylation reaction. 
The nucleophilic attack of the thiol group from the catalytic cysteine residue of the 
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DNMT occurs at the C6 position of azacytosine and results in a covalent bond 
between substrate and enzyme. 
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Figure.6: Nucleoside inhibitors of DNA methyltransferases 
 
As demonstrated above, the covalent can be removed through a ß-elimination 
reaction then the DNMT can be released and recruited. However, because 5-
azacytidine and 5-aza-2’-deoxycytidine have a nitrogen atom in place of the C-5 
carbon atom, ß-elimination is blocked. As a result, the DNA methyltransferases 
remain bound to DNA as intermediates and the function of DNMT is blocked.  In 
addition, covalently trapped DNMTs also compromises the functionality of DNA and 
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triggers DNA damage signaling, resulting in the degradation of trapped DNA 
methyltransferases [3, 4, 11, 18].  
The most critical problems of 5-azacytidine and 5-aza-2’-deoxycytidine are 
toxic side effects and chemical instability. A great caution has been taken when using 
5-azacytidine and 5-aza-2’-deoxycytidine at high doses. For many years, both drugs 
were administered at the maximum tolerated doses because health care providers 
believed that this would bring patients with the most benefit. Under this circumstance, 
however, both drugs can cause severe side effects. It has also been observed that 
the treatment of cultured cell lines with drug in the micromolar concentrations 
prolonged myelosuppression [19, 20]. The other biggest problem for azanucleoside 
inhibitors is chemical instability. In alkaline solutions, the 5-azacytosine ring of 
azanucleosides can be open and decomposed followed by losing inhibition activities. 
While in acidic solutions the glcosidic bond of azanucleosides is cleaved, which 
causes problems in oral administration. [4] As a result, modifications of those 
compounds have continuously implemented and improve plasma stability of 
azanucleosides. SGI-110 is one of the examples, which has a better chemical 
stability in vitro test and a improved resistance to enzymatic deamination [21]. 
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Figure.7 Trapping mechanism of azacytosine. (a) Normal mechanism of DNA methylation. (b) Mechanism-based 
inhibition of DNMTs by azacytosine containing DNA 
Reproduced from Int. J. Cancer: 123, 8-13 (2008) 
 
 
Non-nucleoside inhibitors: Because of the limitation in usage of nucleoside 
analogs in clinical treatment, a particular interests has recently emerged from non-
nucleoside compounds, which exert their inhibitory effects through a variety of 
mechanisms instead of DNA incorporation. Among those compounds RG-108 [22] 
and SGI-1027 [23] are introduced.  
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It has been approved that RG-108 has ability inhibition ability both in purified 
recombinant CpG methylase M.SssI and genomic DNA methylation level of human 
tumor cell line [6]. It occupies the same pocket of the native cytosine substrate. The 
research suggested that it is a mechanism-independent inhibitor because although it 
does not have a ring structure similar to cytosine it has carboxylate anion and 
carbonyl groups of phthalimide, which can form hydrogen bonds with Arginine and 
Cysteine respectively, preventing forming the covalent bond between substrate and 
catalytic cysteine [24]. RG-108 has approved its large range of utilities in inhibition. It 
can interact with human DNMT1 and the catalytic domain of murine DNMT3A [22]. 
SGI-1027 is a quinolone-based compound the study shows that it is a noncompetitive 
type and it probably competes with Ado-Met for access to the cofactor binding site of 
the enzyme. [25] According to the work of Jakyung Yoo and his colleagues [23] the 
quinolylamino benzamide group of SGI-1027 forms hydrogen bonds with many key 
amino acid residues at SAM binding pocket, such as Arg883, Arg887 and Glu660. 
The benzyl aminopyrimidine group of SGI-1027 occupies a region similar to the 
aminopurine ring of SAH. In addition, a benzene ring of both SGI-1027 and 
aminopruine ring of SAH makes π-π stacking interactions with enzyme. Researches 
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has shown the widely use of SGI-1027 in many varieties of human cancer cell lines. It 
shows comparable inhibitory activity of DNMT1, DNMT3A and DNMT3B without 
significant toxicity. It has been also suggested its selectivity in inhibiting DNMT1 
when treating different mammal cancer cells. SGI-1027 can demethylate three 
different TSGs and then results in the reexpression of TSGs, which could be silenced 
due to the methylation of CpG islands in their promoters in human cancer cells [25]. 
 
Figure.8 3D-interaction map displaying SGI-1027, SAH and human DNMT1 (PDB code: 3SWR) 
Produced from  Yoo, J., S. Choi, and J.L. Medina-Franco, Molecular modeling studies of the 
novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the 
mechanism of inhibition of DNMTs. PLoS One, 2013. 8(4): p. e62152. 
Even though RG-108 and SGI-1027 can inhibit DNMTs directly, their details 
mechanism of action remain unknown. At present, there are no non-nucleoside 
DNMT inhibitors in medicine market or entering clinical trail. So it is therefore highly 
significant to develop new DNMT inhibitors. 
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CHAPTER TWO 
RESULTS AND DISCUSSION 
 
Structure Analysis and Ligand Design 	  
 Structure guided ligand design was carried out by utilizing the crystal structure 
of murine DNMT1. The murine model (PDB code: 4DA4) depicts the active state of 
the methyl transfer reaction with the DNA substrate, SAH (byproduct of SAM after 
reaction) and the enzyme DNMT1. Though the crystal structure of the human DNMT1 
in the active form is not available currently, the catalytic site is highly conserved in 
both murine and human models.[1]  
The active site of DNMTs consists of two pockets namely the DNA binding 
pocket and SAM binding pocket. SAM binding pocket shows a high affinity for 
hydrophobic group and DNA binding pocket shows a hydrophilic character. 
According to the analysis of the crystal structure as well as the work from Shijie Chen 
and his colleagues [2], a good inhibitor occupies both the SAM and DNA binding 
pocket. Our goal is to design and synthesize an inhibitor that can mimic the ribose of 
the cytosine, which can be optimized later to occupy the SAM pocket. Our design of 
compound is based on the dibromoenone moiety. The versatility of the 
dibromoenone in terms of its functionality can be utilized to synthesize derivatives 
that can be either a nucleoside or a non- nucleoside inhibitor as shown in Figure.1 
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Figure.1 design strategy of inhibitors from dibromoenone 
 
 
 
 
 
Figure.2 Superimposed models of human and murine DNMTs. Orange: murine DNMT1 (PDB code: 
4DA4); Gray: human DNMT1 (PDB code: 3PTA). Difference in positions and poses of DNA substrate 
is shown. 
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Figure.3 Binding pockets in DNA methyltransferase. SAH-1701 is at the SAM pocket and C49-18 is 
at the DNA pocket 
Binding pocket of DNMT1 	  
The residues those are common to the DNA pocket in Nanerder Singh’s work [3]  
are Pro86, Cys88, Glu128, Arg172, Arg174, Thr320, His321, Gly440, Asn441 and 
Arg318. In Narender Singh’s work, several hydrogen bonds were predicted between 
the inhibitors and enzyme. Arg174 (Arg1313 in 4DA4) can make several hydrogen 
bonds with oxygens in cytosine ring and phosphate group of the DNA substrate. 
Notably, the intermediate formed after the nucleophilic attack of AdoMet can be 
stabilized through interactions between carbonyl oxygen of the cytosine ring and two 
residues - Arg174, Arg318 (Arg1315 in 4DA4). The hydrogen bond between Glu128 
(Glu1269 in 4DA4) and the amino group of the cytosine ring is also very important. It 
can be predicted that Pro1227 can form interaction with amino group of cytosine ring 
	   19	  
as shown in Figure.5 In addition, His321 (Thr1530 in 4DA4) can make a hydrogen 
bond with 3’-hydroxy group. 
                 
Firgure.4 2D-interaction map displaying amino acid residues with a) 2’-deoxycytidine and b) 5-aza-2’-
dexoycytidine. Produced from Singh, N., et al., Molecular modeling and molecular dynamics studies of 
hydralazine with human DNA methyltransferase 1. ChemMedChem, 2009. 4(5): p. 792-9. 
 
 
 Figure.5 3D-interaction map displaying key amino acid residues with cytidine substrate. 
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 Glu1269, Arg1313 and Arg1315 in PDB model 4DA4 are conserved across the 
mammalian models in the active site. These amino acids residues are essential for 
maintaining and stabilizing the binding position between flipped-out target cytidine 
and enzyme, and/or they could play roles in chemical reactions directly.  
Of the three residues, Glu1269 plays a pivotal role during the catalytic process.  
This was confirmed by a mutation experiment for Glu1269 and Arg1315.[4] The 
mutation results in several fold loss of catalytic activity. This could be explained by 
the loss of hydrogen bonding between Glu1269 and cytosine N3, which plays an 
important role at the reactant and at the transition state. It can build a hydrogen bond 
with cytosine N3 so the proton would vibrate between being bonded to Glu1269 and 
to cytosine N3, which would stabilize the transition state.  
Although hydrogen bond between Arg1313, Arg1315 in PDB model 4DA4 and 
cytosine O2 and O4’ are weak in reactant, transition and intermediate, they indeed 
maintain hydrogen bonds through stabilizing electrostatic interaction from near-
hydrogen bonding orientations in all states. [4] These results can provide meaningful 
information for future design of inhibitors. 
 Because a big region of SAM binding pocket is relatively hydrophobic, a 
prediction can be made that the compounds we made will bind at the DNA binding 
pocket, which is more hydrophilic. Compound 15 docking result is shown in figure.5. 
It can bind at the position as the same as where cytosine was. It can build hydrogen 
bonds with most of the key amino acid residues in active site, such as Arg1313, 
Arg1315, Glu1269, Pro1227 and Asn1580. Compound 15 are so close to Glu1269 
that a strong hydrogen bond can be formed, which could make compound 15 to be 
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more competitive. At the same time interactions between arginines and compound 15 
are stronger than that between argnines and cytidine substrate. In addition, the 
hydrogen bond formed between Asn1580 and compound 15 can be helpful for 
stabilizing this intermediate, which is not available in the natural catalytic process. 
According to the SYBYL docking results of compound 15, it occupies the DNA pocket 
with a good affinity, as a result, compound 15 probably will compete with DNA 
substrate when binding to the enzyme during the catalytic process. 
  
 
 
 
 
 
	  	  	  a)	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b)	  
 
 
Because compound 15 is closer to these key amino acid residues, it can be 
predicted that it has a higher affinity than the natural DNA substrate and can provide 
inhibitory activity. Compound 18 was designed to determine the effect of removing 
one carbon from amino acid side chain of compound 15. 	  
Experiment Results 
	  	   In the past several decades, many nucleoside analogs and non-nucleoside 
analog DNMTi have been developed.[5] However they all have some disadvantages, 
for example, toxicity, low sensitivity and low selectivity. A new series of compounds 
are being developed based on 8-oxabicyclo [3.2.1] octane nucleus and 
Figure.6 SYBYL docking results. a) superimposed model of (R)-Exo-15 and Cytidine. (Green: 
Cytidine; Yellow: (R)-Exo-15). b) 3D-interaction map showing key amino acid residues with (R)-
Exo-15 (Green: residues from enzyme) 	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dibromoenone, which have found wide application for natural products and other 
important compounds. [6, 7] 
O
Br
BrHO
HO OH  
                      3,4-dibromo-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol  
 
Scheme 1: retrosynthetic analysis 
O
O
Br
Br
O
HO
Br
Br
O
HO
Br
Br
HO OH
dibromoenone3,4-dibromo-8-oxabicyclo
[3.2.1]octa-3,6-dien-2-ol
3,4-dibromo-8-oxabicyclo
[3.2.1]oct-3-ene-2,6,7-triol
**
 
  For designing DNMT inhibitors, we chose 3,4-dibromo-8-oxabicyclo[3.2.1]oct-
3-ene-2,6,7-triol as the core of the pharmacophore. The Scheme 1 shows the 
retrosynthetic analysis of synthesizing the compounds. The reasoning behind the 
selection of this moiety is to mimic the ribose of the cytidine molecule. In order to 
elucidate the activity of the 4 diastereomers , CBS resolution of the dibromoenone 
was carried out to separate the diastereomers and dihydroxylated using OsO4 and 
NMO. Since the biological activity was exhibited only by (S)-diastereomers, newer 
compounds would be synthesized based on these diasteroemers – 1&2.  
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(S) O
HO
Br
Br
(S) O
HO
Br
Br
(R) O
HO
Br
Br
HO OH
(R) O
HO
Br
Br
HO OHHO OH HO OH
1 2 3 4  
 Initially racemic derivatives of 3,4-dibromo-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-
triol were synthesized to understand the biological profile.  The target product 15 is 
designed according to the structure of the active sites in DNMTs. Our retrosynthetic 
strategy targeted intermediate 14, containing the intact pharmacophore with a Boc-
protection on amine group. The intermediate 14 was thought to arise from the 
dihydroxylation of intermediate 13, which was a result compound from the 
esterification between dibromoenone alcohol and a Beta-amino acid, Boc-ß-Ala-OH. 
Diastereomers of dibromoenone alchols could be synthesized from dibromoenone 
using the method developed by VanHeyst et al [8]  
Scheme 2: retrosynthetic analysis 
O
Br
BrHO
O
Br
BrO
C
H
N
Boc
OO
Br
BrO
C
H
N
Boc
O
HO OH
O
Br
BrO
C
H2N
O
HO OH
O
Br
BrO
1314
Dibromoenone 3,4-dibromo-8-oxabicyclo[3.2.1]
octa-3,6-dien-2-ol
15
Boc deprotection
 
 The reduced product of dibromoenone was obtained using sodium 
borohydride with 95% yields. [9] 
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O
Br
BrHO
O
Br
BrO
C
H
N
Boc
O
Boc-ß-Ala-OH
DMAP, DCC
3,4-dibromo-8-oxabicyclo
[3.2.1]octa-3,6-dien-2-ol
13
 
The esterification between dibromoenone and Boc-ß-Ala-OH is one of the key steps 
in the whole synthesis. At the beginning, Yumiko Yamand’s procedure was employed 
in a Mukaiyama condition.[10] The long reaction time and low yields led to the use of  
Philipp Barbie’s esterification reaction in DMAP and DCC.[11] This method generated 
13 in good yields overnight.  
 
O
Br
BrO
C
H
N
Boc
O O
Br
BrO
C
H
N
Boc
O
OsO4
NMO • H2O
HO OH
13 14  
 
 13 underwent dihydroxylation with OsO4 and NMO. The dihydroxylated 
product 14 was sensitive to silica gel during column resulting in the cleavage of the 
side chain. Hence the product was isolated and taken to the next step of deprotection. 
The reason of the phenomenon is still not clear but probably because that the 
secondary amine group could be as a nucleophilie attacking ester bond and then 
form a 4 membered ring or secondary alcohols would attack ester bond and then 
form a 6 members ring in acidic condition. As a result of both reasons above, the side 
chain would be cleaved and product was destroyed. On the contrary, there was no 
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problem when using Fluorenylmethyloxycarbonyl (Fmoc) group as protection group. 
Maybe Fmoc group hindered the amine group from reaching ester bond so that it 
could not form a stable 6 members ring. 
O
Br
BrO
C
H
N
Boc
O
HO OH
O
Br
BrO
C
H2N
O
HO OH
SnCl4
14 15  
The traditional method of Boc deprotection using trifluoroacetic acid at 1, 7,14 
and 25 equivalent was carried out at low temperature. [12] The same problem of 
side-chain cleavage associated with column purification was observed with this 
deprotection strategy. When ZnBr2 was used no reaction took place. Finally a milder   
method of Boc-deprotection published by Robert Frank and Mike Schutkowski was 
employed.[13] The compound 14 could be deprotected within 3h at the room 
temperature using SnCl4. The resulting oil could be dissolved in methanol and the 
crude product precipitated by adding diethyl ether. Because the impurities were also 
polar and compound 15 was still sensitive to the acidic condition, a pure compound 
was obtained after triturating with ethyl acetate and methanol. 
       
O
Br
BrOCN
H O
Fmoc
HO OH
17                    
O
Br
BrO
CH2N
O
HO OH
18  
 Compound 17 was obtained by the esterification of the alcohol with Fmoc 
glycine. The deprotection method using piperidine in DMF gave the product which 
needs to be purified for further characterization and biological testing.  
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 In conclusion, we have designed and synthesized a new non-nucleoside 
DNMT inhibitor based on dibromoenone. According to the SAR analysis, several key 
amino acid residues have been defined and taken advantage of for designing DNMT 
inhibitors. Future biolgical evaluations of these dibromotrialcohol series might help in 
building lead compounds.  
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CHAPTER THREE 
EXPERIMENTS 
 
General procedures: All reactions were carried out under an inert argon atmosphere 
with dry solvent under anhydrous conditions unless otherwise stated. Commercial 
grade reagents and solvents were used without further purification except as 
indicated below. Hexanes, tetrahydrofuran (THF), diethyl ether (Et2O), and 
dichloromethane (CH2Cl2) were used directly from a Baker cycle-tainer system. 
Reagents were purchased at the highest commercial quality and used without further 
purification, unless otherwise noted. Yields refer to chromatographically and 
spectroscopically (1H NMR) homogenous materials, unless otherwise stated. 
Reactions were monitored by thin layer chromatography (TLC) carried out on 
Wharman silica 60 Å precoated plates using UV light as the visualizing agent and an 
acidic mixture of anisaldehyde or basic aqueous potassium permanganate (KMnO4) 
and heated as developing agents. Flash chromatography was performed using Baker 
silica gel (60Å particle size). NMR spectra were recorded on Bruker-500 and 400 
instruments and calibrated suing residual undeuterated solvent as internal reference 
(CHCl3 at δ 7.27 ppm 1H NMR, δ 77.0 ppm 13C NMR). The following abbreviations 
ere used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet, b = broad. High-resolution mass spectra (HRMS) were obtained from the 
University of Connecticut Special Facility by electrospray ionization of flight reflectron 
experiments.  
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Experimental Procedures:  
O
Br Br
BrBr
i. Dioxane 90 °C
ii. Acetone (aq), AgNO3
O
Br
BrO
furan dibromoenone 	  
General procedure for one-pot Diels Alder and silver hydrolysis: To 
a flame dried pressure vessel was added furan  (110 mmol) and solvate with 1,4-
dioxane (24 mL). The solution was treated with freshly distilled TBCP (38.9 g, 110 
mmol) at r.t then the vessel was sealed. The vessel was stirred overnight at r.t before 
gradually heated to 80 °C and held at that temperature until all starting material was 
consumed in about 2h. After this time, the reaction was allowed to cool to r.t, diluted 
with acetone (224 mL) and treated with 2 equivalent AgNO3 (aq) (37 g, 220 mmol in 
122 mL of H2O) over 20 min. The suspension was allowed to stir at r.t for 3h before 
being poured over solid NaHCO3  (37 g, 440 mmol) slowly. The solids were removed 
by filtration through Celite and washed with acetone with acetone (300 mL). The 
filtrate was concentrated and then extracted with Et2O (4 x 100 mL). The combined 
organic layers were washed with sat. NaHCO3 (2 x 100 mL), H2O (3 x 100 mL), brine 
(2 x 100 mL) dried over sodium sulfate and concentrated. The resulting crude 
dibromoenone was purified by flash chromatography using 25 % EtOAc in hexanes 
as the eluent to afford products as yellow solids. The spectral data of it was 
consistent to previous work done in the lab. Yield is 94mmol (85%) 
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O
Br
BrO
O
Br
PhOC6H5B(OH)2
CsCO3, PdCl2(PPh3)2
dibromoenone 3-bromo-4-phenyl-8-oxabicyclo
[3.2.1]octa-3,6-dien-2-one  
General procedure for Suzuki Coupling:  To a flask starting material 
(0.286 mmol, 80 mg) and phenylboronic acid (0.457 mmol, 55.72 mg) were added in 
a solution system (0.2 M; THF, 1.3 mL; H2O, 0.13 mL) under the inert argon 
atmosphere followed by adding CsCO3. The solution was stirred at r.t for 15 minutes 
at which time PdCl2(PPh3)2 was added. Following the consumption of all starting 
material the reaction was quenched with brine. The crude reaction mixture was 
extracted using EtOAc (3 x 25 mL) then washed with brine and dried over sodium 
sulfate. The resulting crude compound was separated from impurities through the 
flash chromatography using 10 % EtOAc in hexanes. Yield is 0.1mmol (35%). 
 
O
Br
PhO
O
Br
PhHO
(R)-(+)or (S)-(-)-CBS cat.
catecholborane, DCM,
4°C, 2h
*
3-bromo-4-phenyl-8-oxabicyclo
[3.2.1]octa-3,6-dien-2-one
3-bromo-4-phenyl-8-oxabicyclo
[3.2.1]octa-3,6-dien-2-ol 	  
General procedure for CBS reduction: To a flame dried flask was added 
substrate in CH2Cl2 (0.3 M) followed by adding (R)-(+) or (S)-(-)-CBS catalyst (50 
mol%).  The solution was stirred at r.t for about 20 minutes at which time the reaction 
was cooled down to 4 °C and then catecholborane (150 mol%) was added. After the 
consumption of all starting material, the reaction was quenched with 15 % NaOH and 
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allowed to stir at r.t for 1h. The aqueous layer was extracted with CH2Cl2 (3 x 0.05M). 
The combined organic layers were washed with 15% NaOH (3 x 0.05 M) water and 
birne, dried over sodium sulfate and concentrated. The resulting diastereomers were 
separated and purified by flash chromatography (SiO2, 1:200 g) using 5% EtOAc in 
hexanes as the eluent to afford products as white solids. 
 
O
Br
PhHO
HO OH
O
Br
PhHO
OsO4
NMO • H2O
3,4-dibromo-8-oxabicyclo
[3.2.1]octa-3,6-dien-2-ol
3-bromo-4-phenyl-8-oxabicyclo
[3.2.1]oct-3-ene-2,6,7-triol 	  
General procedure for Dihydroxylation: To a flask was added starting 
material (0.71 mmol, 200 mg) in solution (7.1 mL; Acetone, 5.68 mL; H2O, 1.42 mL) 
followed by NMO • H2O (4-Methylmorpholine N-Oxidate Monohydrate, 1.77 mmol, 
239.25 mg). The solution was stirred at r.t for 15 minutes then OsO4 (0.0426 mmol, 
0.271 mL) was added.  After the consumption of all starting material, the reaction was 
quenched with water.  Acetone in solution was removed by vacuum then the 
aqueous layer was extracted with EtOAc (3 x 25 mL). All organic layers were 
combined and washed with brine (100 mL) then dried over sodium sulfate and 
concentrated. The resulting crude compound was separated from impurities through 
the flash chromatography using 25 % EtOAc in hexanes. 
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O
Br
BrHO
O
Br
BrO
C
H
N
Boc
O
Boc-ß-Ala-OH
DMAP, DCC
3,4-dibromo-8-oxabicyclo
[3.2.1]octa-3,6-dien-2-ol 13  
General procedure for esterification: To a flask the substrate (0.142 
mmol, 40 mg) and Boc-ß-Ala-OH (0.142 mmol, 26.87 mg) were added in solution 
(0.16M Et2O, 0.9 mL). DMAP was added to the flask then solution was stirred until it 
became into clear, at which time the solution was cooled to 0 °C for 10 minutes then 
added DCC and the solution was allowed to warm to r.t and leave it overnight. 
Following the consumption of all starting materials the suspension was filtered and 
filtrate was washed with sat. sodium bicarbonate (3 x 25 mL) and brine (25 mL) then 
dried over sodium sulfate and concentrated. The resulting crude compound was 
purified using flash chromatography with 10% EtOAc in hexanes. 
 
O
Br
BrO
C
H
N
Boc
O
HO OH
O
Br
BrO
C
H2N
O
HO OH
SnCl4
14 15 	  
Procedure for Boc Deprotection: The stirring solution of starting material 
(0.037mmol, 18mg) in EtOAc, the SnCl4 (0.074mmol, 0.074mL) was added at r.t. The 
resulting solution turning from clear into cloudy was stirred until TLC analysis showed 
all starting material has been consumed after 3 hours. Then the solvent was 
evaporated in vacuum and the remaining oil dissolved in methanol and the product 
	   35	  
precipitated after adding diethyl ether. The solid was washed with diethyl ether twice 
and dried in the vacuum. The crude product was recrystallized by the solvent system 
of acetyl acetate-hexane, yielding 7.35mg, 0.019mmol (50%) 
(1R,2S,5S,6S,7R)-3,4-dibromo-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(S) O
HO
Br
Br
HO OH
1 	  
1H NMR (500 MHz, DMSO-d6) δ 6.15 (s, 1H), 5.17 (s, 1H), 5.07 (s, 1H), 4.52 (d, J = 
6.2 Hz, 1H), 4.42 (s, 1H), 4.34 (s, 1H), 4.16 (d, J = 5.6 Hz, 1H), 4.03 (d, J = 6.1 Hz, 
1H).13C NMR (126 MHz, MeOD) δ 141.62, 137.08, 128.19, 128.16, 128.02, 122.97, 
86.47, 86.42, 73.33, 70.29, 69.23; HRMS (DART) calcd for C7H8Br2O4 [M+H]+: 
314.8868 
 
(1S,2S,5R,6R,7S)-3,4-dibromo-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(S) O
HO
Br
Br
HO OH
2 	  
1H NMR (500 MHz, DMSO-d6) δ 5.97 (d, J = 7.5 Hz, 1H), 5.24 (s, 1H), 5.03 (d, J = 
5.9 Hz, 1H), 4.42 (s, 1H), 4.06 (s, 1H), 4.03 (d, J = 6.0 Hz, 1H), 3.99 (d, J = 4.0 Hz, 
1H), 3.83 (d, J = 7.0 Hz, 1H).13C NMR (126 MHz, MeOD) δ 125.96, 123.33, 88.27, 
86.84, 73.36, 72.47, 71.54. HRMS (DART) calcd for C7H8Br2O4 [M+NH4]+: 333.9113 
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(1R,2R,5S,6S,7R)-3,4-dibromo-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(R) O
HO
Br
Br
HO OH
3 	  
1H NMR (500 MHz, DMSO-d6) δ 5.97 (dd, J = 7.8, 2.9 Hz, 1H), 5.23 (d, J = 5.3 Hz, 
1H), 5.02 (d, J = 6.0 Hz, 1H), 4.41 (s, 1H), 4.06 (d, J = 3.4 Hz, 1H), 4.02 (t, J = 6.3 
Hz, 1H), 3.98 (t, J = 5.6 Hz, 1H), 3.82 (dd, J = 8.0, 1.5 Hz, 1H).13C NMR (126 MHz, 
MeOD) δ 125.96, 123.33, 88.27, 86.84, 73.36, 72.47, 71.54. HRMS (DART) calcd for 
C7H8Br2O4 [M+NH4]+: 333.9113  
 
(1S,2R,5R,6R,7S)-3,4-dibromo-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(R) O
HO
Br
Br
HO OH
4 	  
1H NMR (500 MHz, DMSO-d6) δ 6.15 (d, J = 6.7 Hz, 1H), 5.16 (d, J = 5.3 Hz, 1H), 
5.06 (d, J = 6.9 Hz, 1H), 4.52 (t, J = 6.6 Hz, 1H), 4.41 (t, J = 6.1 Hz, 1H), 4.34 (s, 1H), 
4.16 (d, J = 5.6 Hz, 1H), 4.03 (t, J = 5.8 Hz, 1H).13C NMR (126 MHz, MeOD) δ 
127.12, 123.34, 87.53, 86.22, 73.07, 70.34, 69.97. HRMS (DART) calcd for 
C7H8Br2O4 [M+H]+: 314.8868 
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(1R,2S,5S)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-ol 
(S) O
HO
Br
Ph
5 	  
1H NMR (500 MHz, Chloroform-d) δ 7.49 – 7.33 (m, 5H), 6.90 (dd, J = 6.0, 1.7 Hz, 
1H), 6.34 (dd, J = 5.9, 1.8 Hz, 1H), 5.33 (dd, J = 6.1, 1.9 Hz, 1H), 4.98 (d, J = 1.7 Hz, 
1H), 4.65 (t, J = 5.3 Hz, 1H), 2.21 (d, J = 5.0 Hz, 1H).13C NMR (126 MHz, CDCl3) δ 
146.53, 140.81, 136.51, 129.30, 128.51, 127.84, 121.61, 83.13, 81.78, 67.93, 29.72. 
HRMS (DART) calcd for C13H11BrO2 [M-OH]+: 260.9915 
 
(1S,2S,5R)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-ol 
(S) O
HO
Br
Ph
6 	  
1H NMR (500 MHz, Chloroform-d) δ 7.50 – 7.33 (m, 5H), 6.87 (dd, J = 6.0, 1.7 Hz, 
1H), 6.33 (dd, J = 6.0, 1.9 Hz, 1H), 5.11 (dd, J = 19.3, 1.8 Hz, 2H), 3.91 (d, J = 7.9 
Hz, 1H), 2.59 (d, J = 8.1 Hz, 1H).13C NMR (126 MHz, CDCl3) δ 147.84, 141.55, 
136.53, 128.54, 128.49, 128.17, 127.87, 118.82, 84.46, 82.31, 70.19, 29.73. HRMS 
(DART) calcd for C13H11BrO2 [M+NH4]+: 296.0286 
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(1R,2S,5R,6S,7R)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(S) O
HO
Br
Ph
HO OH
7 	  
1H NMR (500 MHz, Methanol-d4) δ 7.49 – 7.28 (m, 5H), 4.81 (d, J = 6.1 Hz, 1H), 4.56 
(d, J = 5.9 Hz, 1H), 4.50 (s, 1H), 4.32 (d, J = 5.7 Hz, 1H), 4.17 (d, J = 6.2 Hz, 1H).13C 
NMR (126 MHz, MeOD) δ 141.62, 137.07, 128.19, 128.16, 128.02, 122.97, 86.47, 
86.42, 73.33, 70.29, 69.23. HRMS (DART) calcd for C13H13BrO4 [M-OH]+: 294.9970 
 
(1S,2S,5S,6R,7S)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(S) O
HO
Br
Ph
HO OH8 	  
1H NMR (500 MHz, Methanol-d4) δ 7.48 – 7.29 (m, 5H), 4.57 (s, 1H), 4.27 (d, J = 1.3 
Hz, 1H), 4.21 (d, J = 6.0 Hz, 1H), 4.11 (d, J = 6.1 Hz, 1H), 3.91 (d, J = 1.2 Hz, 
1H).13C NMR (126 MHz, MeOD) δ 143.61, 138.28, 129.47, 129.41, 129.36, 120.84, 
89.52, 86.73, 73.80, 73.30, 72.94.  HRMS (DART) calcd for C13H13BrO4 [M+NH4]+: 
330.0341 
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(1R,2R,5S)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-ol 
(R) O
HO
Br
Ph
9 	  
1H NMR (500 MHz, Chloroform-d) δ 7.49 – 7.33 (m, 5H), 6.88 (dd, J = 5.9, 1.8 Hz, 
1H), 6.33 (dd, J = 6.0, 2.0 Hz, 1H), 5.13 (d, J = 2.0 Hz, 1H), 5.09 (d, J = 1.8 Hz, 1H), 
3.91 (d, J = 8.1 Hz, 1H), 2.56 (s, 1H).13C NMR (126 MHz, CDCl3) δ 147.86, 141.57, 
136.53, 128.54, 128.50, 128.17, 127.86, 118.82, 84.45, 82.32, 70.19. HRMS (DART) 
calcd for C13H11BrO2 [M+H]+: 296.0286 
 
(1S,2R,5R)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-ol 
(R) O
HO
Br
Ph
10 	  
1H NMR (500 MHz, Chloroform-d) δ 7.56 – 7.33 (m, 5H), 6.90 (dd, J = 6.0, 1.7 Hz, 
1H), 6.34 (dd, J = 5.9, 1.8 Hz, 1H), 5.33 (dd, J = 6.1, 1.8 Hz, 1H), 4.98 (d, J = 1.7 Hz, 
1H), 4.65 (t, J = 5.2 Hz, 1H), 2.26 (d, J = 4.7 Hz, 1H).13C NMR (126 MHz, CDCl3) δ 
146.52, 140.80, 136.52, 129.31, 128.51, 128.38, 127.84, 121.62, 83.13, 81.80, 
67.93. HRMS (DART) calcd for C13H11BrO2 [M-OH]+: 260.9915 
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(1R,2R,5R,6S,7R)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(R) O
HO
Br
Ph
HO OH
11 	  
1H NMR (500 MHz, Methanol-d4) δ 7.47 – 7.30 (m, 5H), 4.61 (d, J = 1.0 Hz, 1H), 4.31 
(q, J = 1.3 Hz, 1H), 4.23 (d, J = 6.0 Hz, 1H), 4.13 (d, J = 6.0 Hz, 1H), 3.93 (d, J = 1.3 
Hz, 1H).13C NMR (126 MHz, MeOD) δ 143.61, 138.28, 129.47, 129.41, 129.36, 
120.84, 89.52, 86.73, 73.80, 73.30, 72.94. HRMS (DART) calcd for C13H13BrO4 [M-
OH]+: 294.9970 
 
(1S,2R,5S,6R,7S)-3-bromo-4-phenyl-8-oxabicyclo[3.2.1]oct-3-ene-2,6,7-triol 
(R) O
HO
Br
Ph
HO OH
12 	  
1H NMR (500 MHz, Methanol-d4) δ 7.47 – 7.29 (m, 5H), 4.81 (d, J = 6.1 Hz, 1H), 4.61 
– 4.53 (m, 1H), 4.50 (s, 1H), 4.32 (d, J = 5.8 Hz, 1H), 4.17 (d, J = 6.2 Hz, 1H). 13C 
NMR (126 MHz, MeOD) δ 141.62, 137.07, 128.19, 128.16, 128.02, 122.96, 86.47, 
86.42, 73.33, 70.29, 69.23. HRMS (DART) calcd for C13H13BrO4 [M-OH]+: 294.9970 
 
 
	   41	  
 
 
3,4-dibromo-8-oxabicyclo[3.2.1]octa-3,6-dien-2-yl3-
{[(tertbutoxy)carbonyl]amino}propanoate 
 
 
O
Br
BrOC
H
N
Boc
O
13  
1H NMR (500 MHz, Methanol-d4) δ 6.96 (dd, J = 5.9, 1.9 Hz, 1H), 6.36 – 6.26 (m, 
1H), 5.78 (d, J = 6.0 Hz, 1H), 5.26 (dd, J = 6.0, 2.0 Hz, 1H), 4.95 (d, J = 1.8 Hz, 1H), 
3.37 – 3.29 (m, 2H), 2.59 (t, J = 6.5 Hz, 2H), 1.45 (s, 9H).13C NMR (126 MHz, MeOD) 
δ 170.79, 138.74, 131.08, 129.90, 118.75, 84.05, 83.56, 82.45, 79.58, 79.41, 78.84, 
69.55, 35.96, 33.99, 27.39. HRMS (DART) calcd for C15H19Br2NO5 [M+H]+: 453.9689 
 
3,4-dibromo-6,7-dihydroxy-8-oxabicyclo[3.2.1]oct-3-en-2-yl 3- 
{[(tert-butoxy)carbonyl]amino}propanoate 
 
O
Br
BrOC
H
N
Boc
O
HO OH
14  
1H NMR (500 MHz, Methanol-d4) δ 5.76 (d, J = 5.5 Hz, 1H), 4.60 (d, J = 6.4 Hz, 1H), 
4.50 (s, 1H), 4.43 – 4.35 (m, 1H), 4.25 (d, J = 6.2 Hz, 1H), 3.41 – 3.33 (m, 2H), 2.63 
(t, J = 6.8 Hz, 2H), 1.43 (s, 10H).13C NMR (126 MHz, MeOD) δ 171.97, 127.92, 
122.10, 89.09, 84.89, 74.65, 72.44, 72.23, 37.35, 35.53, 28.83. HRMS (DART) calcd 
for C15H21Br2NO5 [M+H]+: 487.9744 
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3,4-dibromo-6,7-dihydroxy-8-oxabicyclo[3.2.1]oct-3-en-2-yl 3-aminopropanoate 
O
Br
BrOC
H2N
O
HO OH
15
 
 
1H NMR (500 MHz, Methanol-d4) δ 5.84 (d, J = 5.5 Hz, 1H), 5.76 (d, J = 5.7 Hz, 1H), 
4.58 (q, J = 7.6 Hz, 3H), 4.55 (s, 2H), 4.45 (t, J = 6.4 Hz, 2H), 4.36 (s, 3H), 4.29 (d, J 
= 6.2 Hz, 1H), 3.29 (t, J = 5.1 Hz, 5H), 2.91 (t, J = 6.3 Hz, 7H). HRMS (DART) calcd 
for C10H13Br2NO5 [M+H]+: 387.9219 
 
3,4-dibromo-8-oxabicyclo[3.2.1]octa-3,6-dien-2-yl 2-({[(9H-fluoren-9-
yl)methoxy]carbonyl}amino)acetate 
 
 
O
Br
BrOCN
H O
Fmoc
16  
1H NMR (500 MHz, Chloroform-d) δ 7.82 (d, J = 7.5 Hz, 2H), 7.64 (t, J = 6.2 Hz, 2H), 
7.46 (t, J = 7.5 Hz, 2H), 7.37 (td, J = 7.4, 1.1 Hz, 2H), 6.90 (d, J = 5.9 Hz, 1H), 6.23 
(d, J = 5.9 Hz, 1H), 5.86 (d, J = 5.9 Hz, 1H), 5.40 – 5.26 (m, 2H), 4.96 (d, J = 1.7 Hz, 
1H), 4.48 (d, J = 7.2 Hz, 2H), 4.30 (t, J = 7.0 Hz, 1H), 4.09 (qd, J = 18.4, 5.8 Hz, 
2H).13C NMR (126 MHz, CDCl3) δ 169.23, 156.31, 143.72, 141.36, 139.41, 131.72, 
129.70, 127.81, 127.15, 125.08, 120.07, 118.39, 84.18, 79.54, 70.54, 67.40, 47.11, 
42.67. HRMS (DART) calcd for C24H19Br2NO5 [M+H]+: 561.9690 
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3,4-dibromo-6,7-dihydroxy-8-oxabicyclo[3.2.1]oct-3-en-2-yl 2-({[(9H-fluoren-9-
yl)methoxy]carbonyl}amino)acetate 
 
O
Br
BrOCN
H O
Fmoc
HO OH17  
To a flask compound 16 (0.107mmol, 30mg) and Fmoc-Gly-OH (0.107mmol, 31.8) 
were added in solution (Acetonitrile, 2mL). The suspension was warmed at 35ºC and 
stirred until changing into clear. Then follow the general procedure for esterification. 
1H NMR (500 MHz, Chloroform-d) δ 7.79 (d, J = 7.5 Hz, 2H), 7.59 (t, J = 6.5 Hz, 2H), 
7.43 (t, J = 7.5 Hz, 2H), 7.38 – 7.30 (m, 2H), 5.76 (dd, J = 16.5, 5.5 Hz, 1H), 5.42 (s, 
1H), 4.62 (t, J = 5.5 Hz, 1H), 4.60 (s, 1H), 4.52 (d, J = 5.6 Hz, 1H), 4.51 – 4.39 (m, 
3H), 4.25 (dq, J = 15.4, 8.4, 7.3 Hz, 2H), 4.09 – 3.96 (m, 2H). 
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APPENDIX SELECTED SPECTRA 
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